Literature DB >> 32650408

Molecular Features of Metaplastic Breast Carcinoma: An Infrequent Subtype of Triple Negative Breast Carcinoma.

Silvia González-Martínez1, Belén Pérez-Mies2,3,4,5,6, Irene Carretero-Barrio2, María Luisa Palacios-Berraquero7, José Perez-García8, Javier Cortés4,8,9,10,11,12, José Palacios2,3,4,5,6.   

Abstract

Metaplastic breast carcinoma (MBC) is a heterogeneous group of infrequent invasive carcinomas that display differentiation of the neoplastic epithelium towards squamous cells and/or mesenchymal-type elements. Most MBC have a triple negative phenotype and poor prognosis. Thus, MBC have worse survival rates than other invasive breast carcinomas, including other triple negative breast carcinomas (TNBC). In this study, we reviewed the molecular features of MBC, pointing out the differences among subtypes. The most frequently mutated genes in MBC were TP53 and PIK3CA. Additionally, mutations in the other genes of the PI3K/AKT pathway indicated its importance in the pathogenesis of MBC. Regarding copy number variations (CNVs), MYC was the most frequently amplified gene, and the most frequent gene loss affected the CDKN2A/CDKN2B locus. Furthermore, the pattern of mutations and CNVs of MBC differed from those reported in other TNBC. However, the molecular profile of MBC was not homogeneous among histological subtypes, being the alterations in the PI3K pathway most frequent in spindle cell carcinomas. Transcriptomic studies have demonstrated an epithelial to mesenchymal program activation and the enrichment of stemness genes in most MBC. In addition, current studies are attempting to define the immune microenvironment of these tumors. In conclusion, due to specific molecular features, MBC have a different clinical behavior from other types of TNBC, being more resistant to standard chemotherapy. For this reason, new therapeutic approaches based on tumor molecular characteristics are needed to treat MBC.

Entities:  

Keywords:  MBC; metaplastic breast carcinoma; molecular alterations; prognosis; treatment

Year:  2020        PMID: 32650408     DOI: 10.3390/cancers12071832

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  9 in total

1.  Metaplastic Matrix-Producing Carcinoma and Apocrine Lobular Carcinoma In Situ Associated with Microglandular Adenosis: A Unique Case Report.

Authors:  Nektarios Koufopoulos; Dionysios Dimas; Foteini Antoniadou; Kyparissia Sitara; Dimitrios Balalis; Ioannis Boutas; Alina Roxana Gouloumis; Adamantia Kontogeorgi; Lubna Khaldi
Journal:  Diagnostics (Basel)       Date:  2022-06-13

2.  Prognostic Factor Analysis and Model Construction of Triple-Negative Metaplastic Breast Carcinoma After Surgery.

Authors:  Keying Zhu; Yuyuan Chen; Rong Guo; Lanyi Dai; Jiankui Wang; Yiyin Tang; Shaoqiang Zhou; Dedian Chen; Sheng Huang
Journal:  Front Oncol       Date:  2022-06-23       Impact factor: 5.738

Review 3.  An Update on the Molecular Pathology of Metaplastic Breast Cancer.

Authors:  Amy E McCart Reed; Emarene M Kalaw; Sunil R Lakhani
Journal:  Breast Cancer (Dove Med Press)       Date:  2021-02-26

4.  PIK3CA mutation confers resistance to chemotherapy in triple-negative breast cancer by inhibiting apoptosis and activating the PI3K/AKT/mTOR signaling pathway.

Authors:  Huayu Hu; Junyong Zhu; Yuting Zhong; Rui Geng; Yashuang Ji; Qingyu Guan; Chenyan Hong; Yufan Wei; Ningning Min; Aiying Qi; Yanjun Zhang; Xiru Li
Journal:  Ann Transl Med       Date:  2021-03

5.  Screening of Specific and Common Pathways in Breast Cancer Cell Lines MCF-7 and MDA-MB-231 Treated with Chlorophyllides Composites.

Authors:  Keng-Shiang Huang; Yi-Ting Wang; Omkar Byadgi; Ting-Yu Huang; Mi-Hsueh Tai; Jei-Fu Shaw; Chih-Hui Yang
Journal:  Molecules       Date:  2022-06-20       Impact factor: 4.927

6.  Establishment of prognostic model for postoperative patients with metaplastic breast cancer: Based on a retrospective large data analysis and Chinese multicenter study.

Authors:  Ge Wang; Xiaomin Sun; Xin Ren; Mengmeng Wang; Yongsheng Wang; Shukun Zhang; Jingye Li; Wenping Lu; Baogang Zhang; Pingping Chen; Zhiqiang Shi; Lijuan Liu; Jing Zhuang
Journal:  Front Genet       Date:  2022-08-25       Impact factor: 4.772

7.  Nomogram for the prediction of triple-negative breast cancer histological heterogeneity based on multiparameter MRI features: A preliminary study including metaplastic carcinoma and non- metaplastic carcinoma.

Authors:  Qing-Cong Kong; Wen-Jie Tang; Si-Yi Chen; Wen-Ke Hu; Yue Hu; Yun-Shi Liang; Qiong-Qiong Zhang; Zi-Xuan Cheng; Di Huang; Jing Yang; Yuan Guo
Journal:  Front Oncol       Date:  2022-09-20       Impact factor: 5.738

8.  The genetic landscape of metaplastic breast cancers and uterine carcinosarcomas.

Authors:  Lea A Moukarzel; Lorenzo Ferrando; Arnaud Da Cruz Paula; David N Brown; Felipe C Geyer; Fresia Pareja; Salvatore Piscuoglio; Anastasios D Papanastasiou; Nicola Fusco; Caterina Marchiò; Nadeem R Abu-Rustum; Rajmohan Murali; Edi Brogi; Hannah Y Wen; Larry Norton; Robert A Soslow; Anne Vincent-Salomon; Jorge S Reis-Filho; Britta Weigelt
Journal:  Mol Oncol       Date:  2021-02-19       Impact factor: 6.603

9.  A Machine Learning Approach to Differentiate Two Specific Breast Cancer Subtypes Using Androgen Receptor Pathway Genes.

Authors:  Taobo Hu; Guiyang Zhao; Yiqiang Liu; Mengping Long
Journal:  Technol Cancer Res Treat       Date:  2021 Jan-Dec
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.